Perspective Therapeutics (NYSE:CATX) Receives Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a report published on Wednesday morning,Benzinga reports. The brokerage currently has a $10.00 target price on the stock.

Several other equities research analysts have also weighed in on CATX. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday. Cantor Fitzgerald upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $16.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, January 14th. Oppenheimer lowered their price objective on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research note on Friday, November 22nd. Finally, Bank of America lowered Perspective Therapeutics from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $24.00 to $5.00 in a research note on Monday, November 25th. One research analyst has rated the stock with a hold rating, eight have given a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Trading Down 3.7 %

CATX stock opened at $2.36 on Wednesday. Perspective Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.05. The business’s 50 day moving average is $3.07 and its 200-day moving average is $6.99.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of CATX. Victory Capital Management Inc. lifted its holdings in Perspective Therapeutics by 328.7% during the 3rd quarter. Victory Capital Management Inc. now owns 50,460 shares of the company’s stock worth $674,000 after buying an additional 38,690 shares in the last quarter. CIBC Asset Management Inc acquired a new position in Perspective Therapeutics during the 3rd quarter worth $259,000. LMR Partners LLP acquired a new position in Perspective Therapeutics during the 3rd quarter worth $400,000. Intech Investment Management LLC acquired a new position in Perspective Therapeutics during the 3rd quarter worth $137,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Perspective Therapeutics by 221.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 433,522 shares of the company’s stock worth $5,788,000 after buying an additional 298,778 shares in the last quarter. Institutional investors and hedge funds own 54.66% of the company’s stock.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.